Mechanisms of β-N-methylamino-L-alanine induced neurotoxicity

Amyotrophic Lateral Sclerosis

Volumn 10, Issue SUPPL. 2, 2009, Pages 56-60

  Lobner, Doug ^a  

^a MARQUETTE UNIVERSITY   (United States)

Author keywords

BMAA; Cystine; Excitotoxicity; Glutamate; System xc

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROTOXIN;

CONFERENCE PAPER; EXCITOTOXICITY; HUMAN; MOTONEURON; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

AMINO ACIDS, DIAMINO; ANIMALS; CELL DEATH; CYSTINE; EXCITATORY AMINO ACID AGONISTS; GLUTAMIC ACID; HUMANS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; OXIDATIVE STRESS; RECEPTORS, GLUTAMATE;

EID: 74549219338     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903269062     Document Type: Conference Paper

References (30)

1. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers such as memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1:101-10.
2. Ross SM, Seelig M, Spencer PS. Specific antagonism of excitotoxic action of 'uncommon' amino acids assayed in organotypic mouse cortical cultures. Brain Res. 1987;425: 120-7.
3. Weiss JH, Choi DW. Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. Science. 1988;241:973-5.
4. Weiss JH, Koh JY, Choi DW. Neurotoxicity of β-N-methylamino-L- alanine (BMAA) and β-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res. 989;497:64-71.
5. Zeevalk GD, Nicklas WJ. Acute excitotoxicity in chick retina caused by the unusual amino acids BOAA and BMAA: effects of MK-801 and kynurenate. Neurosci Lett. 1989; 102:284-90.
6. Pai KS, Shankar SK, Ravindranath V. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices. Neurosci Res. 1993;17: 241-8.
7. Lobner D, Piana PM, Salous AK, Peoples RW β-N-methylamino-L-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis. 2007;25:360-6.
8. Rakonczay Z, Matsuoka Y, Giacobini E. Effects of L-β-N-methylamino- L-alanine (L-BMAA) on the cortical cholinergic and glutamatergic systems of the rat. J Neurosci Res. 1991;29:121-6.
9. Smith SE, Meldrum BS. Receptor site specificity for the acute effects of β-N-methylamino-alanine in mice. Eur J Pharmacol. 1990;187:131-4.
10. Rao SD, Banack SA, Cox PA, Weiss JH. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006;201:244-52.
11. 2+ dependent. Neurosci Lett. 1994;167:93-6.
12. 2+ dependent. Neuroreport. 1995;19:945-8.
13. Strasser U, Lobner D, Behrens MM, Canzoniero LM, Choi DW. Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures. Eur J Neurosci. 1998;10:2848-55.
14. Manzoni OJ, Prezeau L, Bockaert J. β-N-methylamino-L-alanine is a low-affinity agonist of metabotropic glutamate receptors. Neuroreport. 1991;2:609-11.
15. Buisson A, Choi DW. The inhibitory mGluR agonist, S-4-carboxy-3-hydroxy- phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology. 1995;34:1081-7.
16. Genazzani AA, Casabona G, L'Episcopo MR, Condorelli DF, Dell' Albani P , Shinozaki H, Nicoletti F. Characterization of metabotropic glutamate receptors negatively linked to adenylyl cyclase in brain slices. Brain Res. 1993;622:132-8.
17. Zapata J, Hjelmhaug JA, Lobner D. Role of the cystine-glutamate antiporter in β-N-methylamino-L-alanine (BMAA) toxicity. Soc Neurosci Abs. 2007;604:9.
18. Fogal B, Li J, Lobner D, McCullough LD, Hewett SJ. System X(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J Neurosci. 2007;27:10094-105.
19. Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol. 1994;152:3578-85.
20. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M. System xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci. 2006;26:3345-56.
21. Murch SJ, Cox PA , Banack SA, Steele JC, Sacks OW. Occurrence of β-methylamino-L-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004;110:267-9.
22. Uversky VN. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci. 2008;9:507-40.
23. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci. 2004;11:453-65.
24. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. 1996;103: 987-1041.
25. Johannessen JN, Adams JD, Schuller HM, Bacon JP, Markey SP. 1-methyl-4-phenylpyridine (MPP +) induces oxidative stress in the rodent. Life Sci. 1986;38:743-9.
26. Kwon YS, Koh JY, Song DK, Kim HC, Kwon MS, Choi YS, Wie MB. Danthron inhibits the neurotoxicity induced by various compounds causing oxidative damages including beta-amyloid (25-35) in primary cortical cultures. Biol Pharm Bull. 2004;27:723-6.
27. Karamyan VT, Speth RC. Animal models of BMAA neurotoxicity: a critical review. Life Sci. 2008;82:233-46.
28. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev. 1997;25:335-58.
29. Liu H, Wang H, Shenvi S, Hagen TM, Liu RM. Glutathione metabolism during aging and in Alzheimer's disease. Ann N Y Acad Sci. 2004;1019:346-9.
30. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother. 2000;62:236-49.